Cipla shares rise over 1% as pharma major launches obesity, diabetes treatment drug in India

As of 1:39 pm, the stock was trading 1.29% higher at ₹1,510.10 per equity share.

Cipla has the rights to distribute and promote Yurpea, the second brand of Lilly’s tirzepatide in India, after the latter received DCGI approval, it said in a regulatory filing dated December 10.

Yurpea, a one-weekly injectable therapy, will be available on prescription in the KwikPen device format in six strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the drug maker added.

While Lilly will manufacture and supply Yurpeak to Cipla, the latter will distribute the drug across India, including regions beyond metro cities, by utilising its distribution network.

Furthermore, the drug manufacturer will complement the launch with comprehensive patient education and support programs, including guidance on dosing, self-administration, and safe, informed use of the therapy, Cipla stated.

Yurpeak (tirzepatide) will be priced the same as Mounjaro, it added.

Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, the company said.

Commenting on the development, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: “The launch of Yurpeak marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India’s chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitment that define our leadership in chronic diseases and in respiratory care.”

“Our focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are,” Gupta added.

The pharmaceutical company has a total market capitalisation of ₹1.22 lakh crore, as of December 11, 2025, according to data on the NSE.